Yuanyuan Duan

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

D. Heijde, A. Deodhar, W. Maksymowych, 2022, The Lancet.

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

A. Deodhar, Tae-Hwan Kim, B. Combe, 2022, RMD Open.

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

M. Magrey, I. McInnes, J. Merola, 2021, RMD Open.

Body mass index is an independent predictive factor for kidney function evaluated by glomerular filtration rate in a community-dwelling population

Xiaona Wang, Jiao Zhang, P. Ye, 2019, Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.

Effects of TCFA on stent neointimal coverage at 9 months after EXCEL drug-eluting stent implantation assessed by OCT

Li-min Jing, Huiliang Liu, Yi Li, 2022, Herz.

Stent boost subtract imaging for the assessment of optimal stent deployment in coronary ostial lesion intervention: comparison with intravascular ultrasound.

Zhi-geng Jin, Li-min Jing, Jiao Zhang, 2015, International heart journal.

Stent boost subtract imaging for the assessment of optimal stent deployment in coronary ostial lesion intervention: comparison with intravascular ultrasound.

Zhi-geng Jin, Li-min Jing, Jiao Zhang, 2015, International heart journal.

Optical coherence tomography: evaluating the effects of stent boost subtract imaging on stent underexpansion in STEMI patients

M. Zhang, Li-min Jing, Jiao Zhang, 2022, BMC Cardiovascular Disorders.